Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B.
Wai Kay SetoJ FungK-S CheungL-Y MakR W H HuiSze Hang Kevin LiuC-L LaiM-F YuenPublished in: Alimentary pharmacology & therapeutics (2016)
An increased BMI hindered fibrosis regression in patients with chronic hepatitis B during nucleoside analogue treatment, suggesting that control of metabolic risk factors, in addition to virologic suppression via antiviral therapy, might be needed to halt the fibrogenic process in chronic hepatitis B.